



Final Appraisal Recommendation

Advice No: 0614 – February 2014

Bromfenac (Yellox[®]) 0.9 mg/ml eye drops

Submission by Bausch & Lomb UK Ltd

Recommendation of AWMSG

Bromfenac (Yellox[®]) is not recommended for use within NHS Wales for the treatment of postoperative ocular inflammation following cataract extraction in adults.

The applicant company did not present a sufficiently robust comparative clinical analysis or economic analysis to gain approval by AWMSG. No economic analysis was submitted.

Additional note:

- Patients who are currently being treated with bromfenac (Yellox[®]) for the indication stated above should have the option to continue their therapy until they and their clinicians consider it appropriate to stop.

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 1025), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation has been ratified by Welsh Government and will be considered for review every three years.

Marketing authorisation holder on first issue:	Bausch & Lomb UK Ltd
Date of first issue	February 2014
Last reviewed	May 2017

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group. Final Appraisal Recommendation – 0614:
Bromfenac (Yellox[®]) 0.9 mg/ml eye drops. February 2014.



NICE has accredited the process used by the All Wales Medicines Strategy Group (AWMSG) to produce its final appraisal recommendation. Accreditation is valid for 5 years from October 2011. More information on accreditation can be viewed at www.evidence.nhs.uk.

For full details on our accreditation visit: www.nice.org.uk/accreditation.